About this course
Across major cardiovascular outcome trials, sodium-glucose co-transporter 2 (SGLT2) inhibitors have consistently reduced the risk of heart failure (HF) in patients with diabetes and established cardiovascular disease. This e-learning module provides an overview of the latest real-world evidence of SGLT2 inhibitors for the prevention of HF and cardiorenal outcomes.
Upon completion of the educational activity, participants should be able to:
- Understand the burden of HF and the associated guidelines for its prevention
- Apply real-world evidence of SGLT2 inhibitors for the prevention of HF and cardiorenal outcomes
- Utilize the latest robust clinical evidence on the use of SGLT2 inhibitors for treating patients with HF, irrespective of diabetes status.
- Global prevalence of HF and classification
- Guidance on use of biomarkers to screen for patients at risk of HF
- Key findings and implications for clinical practice of the EMPA-REG OUTCOME, DAPA-HF and EMPEROR-Reduced studies
- Role of SGLT2 inhibitors as renal protectants based on the CREDENCE study
1 CME Point Available
A certificate can be downloaded upon successful completion of the quiz. Please use the information on the certificate to claim your CME points.